Pulmocide
Inhaled medicines for the treatment of viral and fungal infections of the respiratory tract
Pulmocide has raised €28M across 1 funding round from 6 investors, most recently a Series B round in Mar 2017. Based in London, UK; founded 2013; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€28M
€27,700,000
Funding rounds
1
Investors
6
distinct backers
Active since
2017-03
latest 2017-03
Funding by year
EUR raised per yearPulmocide — funding by year — interactive chart.
Data table
| Pulmocide — funding by year | |
|---|---|
| 2017 | €28M |
Signals
High confidenceRaise-next likelihood9
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2017-03-01 | Series B | €28M | F-Prime Capital,Johnson & Johnson,Johnson & Johnson Innovation,SR One,SV Life Sciences,Touchstone Innovations | View deal → |